VISEN Pharmaceuticals, an SIP-headquartered innovative biopharmaceutical company focused on endocrine diseases, commenced trading on the main board of HKEX on Mar 21. This has amounted the number of publicly traded companies in SIP to 68, including 19 listed in Hong Kong.

VISEN, founded in 2018 jointly by Ascendis Pharma A/S, Vivo Capital and Sofinnova Investments, strives to establish a recognized and leading franchise in endocrinology with “end-to-end” capabilities that integrate research and discovery, clinical development, commercialization, manufacturing and business development, and become a partner of choice for innovative endocrine treatment.

Following the listing, the company will accelerate the launch and commercialization of innovative drugs in its pipeline, including those for growth hormone deficiency, hypoparathyroidism, and achondroplasia.

By leveraging a dual-driven model that combines in-house R&D with global licensing and partnerships, the company aims to continuously promote innovation and quality improvement in the field of endocrinology, providing patients with endocrine disorders access to higher-quality treatment options.

March 21, 2025